Financial Architects, Inc Vertex Pharmaceuticals Inc Transaction History

Financial Architects, Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Aug 11, 2020	SELL	$225.48 - $295.8 $19,616 - $25,734	-87 Closed	0 $0
Q1 2020 May 07, 2020	BUY	$199.77 - $247.81 $17,379 - $21,559	87 New	87 $21,000
Q2 2019 Aug 14, 2019	SELL	$164.61 - $190.37 $22,551 - $26,080	-137 Closed	0 $0
Q1 2019 May 13, 2019	BUY	$163.73 - $194.7 $22,431 - $26,673	137 New	137 $25,000
Q1 2019 May 03, 2019	SELL	$163.73 - $194.7 $22,431 - $26,673	-137 Closed	0 $0
Q4 2018 Feb 01, 2019	SELL	$151.91 - $192.21 $6,076 - $7,688	-40 Reduced 22.6%	137 $23,000
Q3 2018 Oct 29, 2018	SELL	$167.73 - $192.74 $13,586 - $15,611	-81 Reduced 31.4%	177 $34,000
Q2 2018 Aug 03, 2018	BUY	$145.72 - $169.96 $17,340 - $20,225	119 Added 85.61%	258 $44,000
Q1 2018 Apr 23, 2018	BUY	$151.6 - $177.13 $3,183 - $3,719	21 Added 17.8%	139 $23,000
Q3 2017 Nov 01, 2017	BUY	$148.13 - $162.24 $17,479 - $19,144	118	118 $18,000

1,723

222M

1.58M

1.36M

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $116B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

Get notified when there are updates to the investment portfolio of Financial Architects, Inc, based on Form 13F filings with the SEC.

Stay updated on Financial Architects, Inc with notifications on news.